ALISO VIEJO, Calif., Oct. 24 /PRNewswire/ -- eyeonics, inc.(TM), the developer of the crystalens(R), the first and only FDA approved accommodating intraocular lens, announced today that revenues for the third quarter ended September 30, 2007 totaled $10.0 million, an increase of 127 percent over the prior year's third quarter revenues of $4.4 million. The crystalens has now been implanted in more than 85,000 eyes worldwide. For the nine months ended September 30, 2007 revenues totaled $23.6 million, an increase of 85 percent over the prior year's nine month revenues of $12.8 million.
The crystalens was approved by the FDA in November 2003. During clinical trials, all of the patients who received the crystalens greatly reduced their need for corrective lenses or eyeglasses. The patented crystalens technology is designed to allow the lens to move in the eye in a manner similar to the natural human lens. By using the eye's muscle to move the lens backwards and forwards naturally, patients can focus through a broad range of vision including near, intermediate and far distances. All other approved intraocular lenses are designed to remain fixed in the eye. For more information about the crystalens go to http://www.crystalens.com.
About eyeonics, inc. (TM)
eyeonics, inc. is a privately held medical device company headquartered in Aliso Viejo, CA., founded in 1998. For more information about eyeonics, inc., go to http://www.eyeonics.com, "about us".
CONTACT: Steven J. Naber, Chief Financial Officer of eyeonics, inc.,
+1-949-389-1783; or media, Steve DiMattia of EVC Group, Inc.,
+1-646-201-5445, for eyeonics, inc.
Web site: http://www.eyeonics.com/